Thread: progesterone

How do you guys treat sides with this like from tren or adrol?

Adrol isn't progestogenic, it was once thought that it was but has been disproved... As far as your question, cabergoline tends to be the best anti-p. .5mg twice to 3 times weekly is plenty for a pretty high tren run(or Nandrolone). You can find it on some rc sites, it generally runs about $2/mg

Originally Posted by overburdened

Adrol isn't progestogenic, it was once thought that it was but has been disproved... As far as your question, cabergoline tends to be the best anti-p. .5mg twice to 3 times weekly is plenty for a pretty high tren run(or Nandrolone). You can find it on some rc sites, it generally runs about $2/mg

From what I've read this is the best treatment/preventative

[QUOTE]

Adrol isn't progestogenic, it was once thought that it was but has been disproved... As far as your question, cabergoline tends to be the best anti-p. .5mg twice to 3 times weekly is plenty for a pretty high tren run(or Nandrolone). You can find it on some rc sites, it generally runs about $2/mg [QUOTE]


Please explain what sources provide this information....I have had my suspicions, but I have held back because 1)oxymethelone does not convert to estrogen and 2)people do in fact get gyno / gyno symptoms from anadrol, but yet yet it doesnt convert to estro.


What are your thoughts on this. Thanks
-jdb3

[QUOTE=jdb3;102527][QUOTE]

Adrol isn't progestogenic, it was once thought that it was but has been disproved... As far as your question, cabergoline tends to be the best anti-p. .5mg twice to 3 times weekly is plenty for a pretty high tren run(or Nandrolone). You can find it on some rc sites, it generally runs about $2/mg [QUOTE]


Please explain what sources provide this information....I have had my suspicions, but I have held back because 1)oxymethelone does not convert to estrogen and 2)people do in fact get gyno / gyno symptoms from anadrol, but yet yet it doesnt convert to estro.


What are your thoughts on this. Thanks
-jdb3

[/QUOT
Exactly. why I posted the thread guys do get gyno from adrol and tren as well not from estrogen

Tren gyno is caused by prolactin...i have seen one severe case of gyno from tren....pretty rough

Tren is pretty scary if you're not prepared to handle whatever sides it decides to bring forth

[QUOTE=jdb3;102527][QUOTE]

Adrol isn't progestogenic, it was once thought that it was but has been disproved... As far as your question, cabergoline tends to be the best anti-p. .5mg twice to 3 times weekly is plenty for a pretty high tren run(or Nandrolone). You can find it on some rc sites, it generally runs about $2/mg

Please explain what sources provide this information....I have had my suspicions, but I have held back because 1)oxymethelone does not convert to estrogen and 2)people do in fact get gyno / gyno symptoms from anadrol, but yet yet it doesnt convert to estro.


What are your thoughts on this. Thanks
-jdb3

This is true.. I'd can't aromatise either. More than likely the gyno brought forth when running adrol is simply due to drol binding to shbg, and estrogen/some progestins being displaced from shbg. From everything I've read, and from my own experience(which is quite extensive with drol), this seems to be the best theory. I've found that if drol is not run alongsideprogestins, GGOOD e2 control will usually do the trick... When running with tren(which is an awesome combo!), caber, along with good e2 control is necessary...

There's some excellent info in CHEMICAL MUSCLE ENHANCEMENT by Author L. Rea..

original Poster is HeavyIron, all credit to him a great internet contributor

Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects.

Berstein L, Maximov S, Gershfeld E, Meshkova I, Gamajunova V, Tsyrlina E, Larionov A, Kovalevskij A, Vasilyev D.
Laboratory Oncoendocrinology, N.N. Petrov Research Institute of Oncology, St. Petersburg 197758, Russia. [email protected]

OBJECTIVE: To investigate the short-term hormonal and clinical effects of the aromatase inhibitor letrozole (Femara) in patients with endometrial cancer. MATERIALS AND METHODS: Ten previously untreated, post-menopausal patients (mean age 59 years) with endometrial cancer, predominantly stage I disease, received letrozole 2.5mg per day for 14 days before surgery. Clinical, sonographic, morphologic, cytologic, and hormonal-metabolic parameters (blood estradiol, follicle-stimulating hormone (FSH), luteinizing hormone (LH), glucose, and cholesterol by radioimmunoassay, enzyme immune assay, or enzyme-colorimetric methods; tumor progesterone receptors by ligand-binding assay; and aromatase activity by 3H-water release assay) were evaluated before and after treatment. RESULTS: Treatment was well-tolerated in all patients. In two patients, pain relief in the lower part of the belly and/or decrease in intensity of uterine discharge was reported. In the three cases, substantial decreases in endometrial M-echo (ultrasound) signal were noted; the mean value of this parameter after treatment was 31.1% lower than before treatment.Blood estradiol concentration decreased by an average of 37.8% after letrozole therapy, and tumor progesterone receptor levels and aromatase activity decreased by 34.4 and 17.5%, respectively. Treatment with letrozole did not influence surgery. CONCLUSIONS: These data show that short-term treatment with letrozole in the neoadjuvant setting resulted in some positive clinical changes. Longer-term and larger-scale trials of neoadjuvant letrozole in endometrial cancer are warranted.

PMID: 12381480 [PubMed - indexed for MEDLINE]